StonvexLoading…
StonvexStonvexStonvexCore line items from IRMD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-07-30 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $20.76M | $21.98M | $83.81M | $61.12M | $39.92M |
Operating Income | Not available | $7.24M | $26.15M | $19.05M | $12.22M |
Net Income | Not available | $5.82M | $22.48M | $16.04M | $5.77M |
EPS (Diluted) | $0.46 | $0.45 | $1.75 | $1.25 | $0.82 |
Total Assets | Not available | $114.39M | $108.78M | $114.72M | $106.45M |
Total Liabilities | Not available | $15.88M | $14.16M | $16.37M | $12.15M |
Cash & Equivalents | Not available | $56.37M | $51.16M | $56.53M | $53.00M |
Free Cash Flow OCF − CapEx | Not available | $7.89M | $17.18M | $11.55M | $5.71M |
Shares Outstanding | Not available | 12.78M | 12.78M | 12.72M | 12.72M |